Off-Label Promoter In Chief: President Trump Pushes COVID-19 Therapy
Executive Summary
If the President says over and over again that a drug is approved, does that make it so?
You may also be interested in...
Remdesivir EUA Includes Promotional Limitations Absent From Chloroquine Authorization
Printed materials and promotions must describe Gilead’s drug as authorized, not approved, for treating COVID-19; although similar boilerplate restrictions are part of most of the EUAs issued for diagnostics and equipment to combat the novel coronavirus, they were not included in the authorization for chloroquine/hydroxychloroquine. Remdesivir's new website strongly resembles an approved brand product site.
States Take Unusual Actions To Control On-Label Drug Supply Amidst COVID-19 Shortages
Sixteen US states have issued executive orders or other mandatory directives to preserve hydroxychloroquine and chloroquine for non-COVID-19 patients, while 26 states have issued similar voluntary guidance. The federal government is reserving some of the strategic national stockpile supply of the drugs for non-COVID-19, as private players in the supply chain also join in the efforts to balance on-label use with COVID-related demand.
Supply Chain Truce In COVID-19: Will It Carry Over When Rx Price Debate Resumes?
Manufacturers, insurers, pharmacies and PBMs are united in trying to assure ongoing access to medicines amid the COVID-19 outbreak. Will making common cause in a national emergency mean a more cooperative approach to addressing US drug pricing concerns when normalcy returns?